Advertisement
U.S. markets closed

Zoetis Inc. (ZTS)

NYSE - NYSE Delayed Price. Currency in USD
169.21+0.70 (+0.42%)
At close: 04:00PM EDT
169.47 +0.26 (+0.15%)
After hours: 07:57PM EDT
  • Dividend

    ZTS announced a cash dividend of 0.432 with an ex-date of Apr. 18, 2024

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close168.51
Open168.73
Bid168.88 x 800
Ask172.90 x 800
Day's Range167.41 - 171.14
52 Week Range151.03 - 201.92
Volume3,344,770
Avg. Volume2,739,759
Market Cap77.476B
Beta (5Y Monthly)0.87
PE Ratio (TTM)33.37
EPS (TTM)5.07
Earnings DateMay 02, 2024
Forward Dividend & Yield1.73 (1.03%)
Ex-Dividend DateApr 18, 2024
1y Target Est225.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-11% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ZTS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Zoetis Inc.
    Analyst Report: Zoetis IncZoetis Inc., a 2013 spinoff from Pfizer, focuses on the development, manufacture and commercialization of animal health vaccines and medicines, including parasiticides, anti-infectives, and medicated feed additives. The company develops products for both livestock and companion animals, and distributes its products globally. Zoetis is a component of the S&P 500 and has roughly 14,100 employees.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Business Wire

    Zoetis to Host Webcast and Conference Call on First Quarter 2024 Financial Results

    PARSIPPANY, N.J., March 28, 2024--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2024 financial results and respond to questions from financial analysts during the call.

  • Benzinga

    Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine

    The European Commission announced on Tuesday that it has initiated an investigation into whether Zoetis Inc (NYSE: ZTS hindered the market launch of a competing pain medication for dogs. Zoetis’ Librela is the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs. The medicine is administered monthly and offers a novel pain relief option, particularly relevant for older dogs. The European Commission said that Zoetis, while working on

  • Reuters

    UPDATE 2-Zoetis in EU antitrust crosshairs over rival dog pain medicine

    EU antitrust regulators have started an investigation into whether Zoetis blocked the market launch of a rival pain medicine for dogs, the European Commission said on Tuesday, a move that could result in a hefty fine for the U.S. pet products maker. Antitrust regulators on both sides of the Atlantic have recently cracked down on Big Tech and Big Pharma acquiring start-ups or small rivals in order to shut them down in what is known as killer acquisitions. Zoetis' Librela is currently the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs.